公开(公告)号：KR101101149B1

公开(公告)日：2011-12-30

申请号：KR1020090014664

申请日：2009-02-23

Applicant: 강원대학교산학협력단

Inventor： 정유진 ,  최선심 ,  정은경

IPC: A61K31/7125 ,  C12N15/11 ,  A61P37/00 ,  C07H21/04

Abstract: 본 발명은 Th1 면역반응을 유발하는 CpG 올리고디옥시뉴클레오타이드 및 그 제작 방법에 관한 것으로서, 기존에 마우스에 Th1 면역반응을 유도하는데 최적이라고 알려진 올리고디옥시뉴클레오타이드 1826보다 더 강력한 Th1 면역반응을 유도하는 CpG 올리고디옥시뉴클레오타이드를 인 실리코 방법을 통하여 선별, 제작하고 그 중 두 가지(M5-30 , M6-395)가 마우스 스플레노사이트에서 기존의 올리고디옥시뉴클레오타이드 1826보다 TNF-α와 IFN-γ를 분비하게 하는 능력이 뛰어남을 확인하였다.
TLR-9, CpG 올리고디옥시뉴클레오타이드, 면역반응

公开(公告)号：KR1020090091400A

公开(公告)日：2009-08-28

申请号：KR1020080016640

申请日：2008-02-25

Applicant: 한림대학교 산학협력단 ,  강원대학교산학협력단 ,  강원도

Inventor： 음원식 ,  이병용 ,  정은경 ,  허장현 ,  주진호 ,  박동식 ,  김성수 ,  함헌주 ,  이광재 ,  김경희 ,  박영학

IPC: A61K36/07 ,  A61P35/00

Abstract: A composition containing an Agrocybe chaxingu Huang which has anticancer activity is provided to have the effect of suppressing cell lines of lung cancer, colon cancer, prostate cancer, and cervical cancer. A composition for anticancner comprises Agrocybe chaxingu Huang extract which is extracted at high pressure and with hot water. The Agrocybe chaxingu Huang extract is a hexane fraction, dichloromethane fraction or ethylacetate fraction using hexane, dichloromethane, ethylacetate, and butanol. The composition has suppression effect to solid cancer. The solid cancer is lung cancer, colon cancer, cervical cancer or prostate cancer.

Abstract translation: 提供含有具有抗癌活性的Agrocybe chaxingu Huang的组合物以具有抑制肺癌，结肠癌，前列腺癌和宫颈癌细胞系的作用。 抗癌剂组合物包括高压萃取和热水提取物。 Agrocybe chaxingu Huang提取物是己烷级分，二氯甲烷级分或乙酸乙酯级分，使用己烷，二氯甲烷，乙酸乙酯和丁醇。 该组合物对实体癌具有抑制作用。 实体癌是肺癌，结肠癌，子宫颈癌或前列腺癌。

公开(公告)号：KR1020100095713A

公开(公告)日：2010-09-01

申请号：KR1020090014664

申请日：2009-02-23

Applicant: 강원대학교산학협력단

Inventor： 정유진 ,  최선심 ,  정은경

IPC: A61K31/7125 ,  C12N15/11 ,  A61P37/00 ,  C07H21/04

CPC classification number: A61K31/7125 ,  C12N15/11 ,  Y10S424/81 ,  Y10S514/826 ,  Y10S514/885

Abstract: PURPOSE: A CpG oligodioxynucleotide which induces Th1 immune reaction is provided to improve TNF-alpha and IFN-gamma secretion. CONSTITUTION: A CpG oligodioxynucleotide is produced in silicon by computer program for designing CpG oligodioxynucleotide. The computer program comprises a subroutine having optical motif(GTCGTT) presence, TpC dinucleotide at 5', and a pyrimidine rich portion at 3'. The subroutine additionally comprises palindrome-containing sequence, poly(G) track presence, or 5'-TGAT-3' at 3'. A pharmaceutical composition for preventing or treating infectious diseases, allergy, asthma, or autoimmune diseases contains effective amount of CpG oligodioxynuelotide and pharmaceutically acceptable carrier.

Abstract translation: 目的：提供诱导Th1免疫反应的CpG寡聚核苷酸，以改善TNF-α和IFN-γ分泌。 构成：通过计算机程序在硅中产生CpG寡聚核苷酸，用于设计CpG寡聚半胱氨酸。 计算机程序包括具有光学基序（GTCGTT）存在的子程序，5'处的TpC二核苷酸和3'处的富含嘧啶的部分。 子程序另外包括含回文序列，poly（G）轨迹存在或3'-3'TGAT-3'。 用于预防或治疗感染性疾病，过敏，哮喘或自身免疫性疾病的药物组合物含有有效量的CpG二氧代半乳糖苷和药学上可接受的载体。

公开(公告)号：KR1020100095716A

公开(公告)日：2010-09-01

申请号：KR1020090014668

申请日：2009-02-23

Applicant: 강원대학교산학협력단

Inventor： 정유진 ,  정은경 ,  최선심

IPC: A61K31/711 ,  A61P35/00

CPC classification number: A61K31/711 ,  A61K41/0038

Abstract: PURPOSE: An adjuvant of radiation treatment containing TLR9 ligand is provided to activate immune response and to prevent and treat cancer. CONSTITUTION: A pharmaceutical composition for treating or preventing cancer contains effective amount of TRL9 ligand and pharmaceutically acceptable carrier. The TLR9 ligand is M5-30 of sequence number 5, M6-395 of sequence number 6, or oligodioxynucleotide 1826 of sequence number 7. A pharmaceutical composition for treating or preventing cancer matastasis contains effective mount of TLR9 ligand and pharmaceutically acceptable carrier.

Abstract translation: 目的：提供含有TLR9配体的放射治疗佐剂，以激活免疫反应并预防和治疗癌症。 构成：用于治疗或预防癌症的药物组合物含有有效量的TRL9配体和药学上可接受的载体。 TLR9配体是序列号5的M5-30，序列号6的M6-395或序列号7的寡聚核苷酸1826.用于治疗或预防癌症转移的药物组合物含有有效载体的TLR9配体和药学上可接受的载体。